Shares of Allergan Inc. skidded Wednesday and Regeneron Pharmaceuticals Inc. shares climbed after Allergan announced a delay in the development of an eye drug that could compete with Regeneron's product Eylea. Full story
Shares of cosmetic drug and device maker Allergan Inc. fell 12 percent Wednesday after company executives said they would delay late-stage testing of an experimental eye treatment by one to two years. Full story
(Reuters) - U.S. specialty drugmaker Allergan Inc said late on Tuesday that it would buy MAP Pharmaceuticals Inc for about $958 million in cash, an acquisition intended to widen its presence in the treatment of adult migraines. Full story
David Pyott, Allergan president and CEO discusses his company's 2012 outlook and the Botox market.
Allergan filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladders. David Pyott, chairman & CEO of Allergan, offers insight on Botox and its many uses.
CNBC's Jim Cramer gives his take on six stocks in 60 seconds, including Oracle, Allergan, Southwest Airlines and others.
Allergan is finding ways to deliver returns for investors in a struggling market and discussing business strategies behind the brand, with David Pyott, Allergan chairman/CEO.
David Pyott, CEO of Allergan, speaks during the Reuters Health Summit in New York, May 9, 2011. REUTERS/Brendan McDermid
